Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

Fifty-seven stage 4 patients with refractory/relapsed neuroblastoma were enrolled in a phase I trial (Clinicaltrials.gov NCT01757626) using humanized anti-GD2 monoclonal antibody hu3F8 in combination with granulocyte-macrophage colony-stimulating factor. The influence of body weight and human anti-h...

Full description

Bibliographic Details
Main Authors: Irene Y. Cheung, Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung
Format: Article
Language:English
Published: Taylor & Francis Group 2017-11-01
Series:OncoImmunology
Subjects:
anti-gd2 antibody
body weight
hu3f8
immunogenicity
pharmacokinetics
vaccination effect
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1358331

Internet

http://dx.doi.org/10.1080/2162402X.2017.1358331

Similar Items